Clinical Trials and Research Weekly Roundup | Imperial College of London Vaccine to be Tested in Uganda by December 2020

Aug 24, 2020 | Digital Media, Video, Weekly Roundup

TrialSite News Weekly Roundup
Imperial College of London Vaccine to be Tested in Uganda by December 2020: The Uganda Virus Research Institute (UVRI) aligned with Imperial College of London to launch the country’s first COVID-19 vaccine clinical trial by December 2020. With the final internal processes and procedures underway, Professor Pontiano Kaleebu reports the team is authoring the protocol directing the trial associated with the vaccine under development by Imperial College London of the United Kingdom. The first phase trial will center on safety and immunogenicity. https://www.trialsitenews.com/imperia…
 
Patients in Touch with TrialSite Seeking Help to Access RLF-100 While FDA Approved IND: TrialSite News, an online digital media and social engagement platform dedicated to open, accessible, and transparent clinical research, receives messages from patients on a daily basis. With COVID-19, an urgency has raised the stakes of each and every communication. Recently, multiple patients were in touch, asking for TrialSite’s support in a desperate bid to help them figure out how to access RLF-100 for severely ill family members infected with SARS-CoV-2. As in one case, a woman’s husband lies in a San Antonio hospital in critical condition with COVID-19-related breathing problems. On a ventilator, the patient’s wife read TrialSite recently and extended outreach to the team for any suggestions. TrialSite explained the emergency use access concept and suggested she contact her husband’s medical team at the hospital immediately to see if that was available. Additionally, TrialSite sent an email communication to the CEO of NeuroRx Inc., the partner to the actual intellectual property owner, Swiss-based Relief Therapeutics (RELIEF). Why? The wife of the critically ill husband was told of significant success with RLF-100 at Houston Methodist Hospital (TrialSite wrote about this as well). TrialSite did what was possible, given its limitations as a non-medical information intermediary, to help this Texas-based family. The situation isn’t good, but one piece of promising news is that the U.S. Food and Drug Administration (FDA) recently announced that NeuroRx was granted a recently requested Investigational New Drug (IND) application to test RLF-100 (Aviptadil) for inhaled use in patients with moderate to severe COVID-19 in order to prevent progression to respiratory failure. This opens up new potential use cases for this investigational product that shows considerable promise against COVID-19. https://www.trialsitenews.com/patient…
 
Ivermectin Breaking into American News as Doctors Come Forward & Share Treatments for COVID-19: Dr. Lauren Mickey, an ears, eyes and throat specialist at Glenwood Medical Mall in West Monroe, Louisiana, was recently interviewed by local television station Fox 14, reporting that the cheap and widely available medication Ivermectin is being used at this provider’s practice—successfully treating COVID-19 patients, reports the news station. https://www.trialsitenews.com/ivermec…
 
University of Minnesota Investigators: Apilimod 5X More Potent Against COVID-19 than Remdesivir in Cell Culture: Researchers led by Ricardo Battaglino, PhD, with the University of Minnesota Medical School, see significant promise for the anti-cancer drug apilimod. The university recently reported that early results show that apilimod is five times more effective in treating cell cultures with COVID-19 as compared to remdesivir. Will this benefit translate to clinical trials? In the power of science, Sanford Burnham Prebys Medical Discovery Institute identified apilimod as one of 21 drugs that could strongly act against COVID-19 https://www.trialsitenews.com/univers…
SHOW LESS
 
 
 
 

0 Comments

Pin It on Pinterest